Biolyst › CABACabaletta Bio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 15.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Upcoming catalysts
Date Event Type Phase
November 12, 2026 est.
Next quarterly earnings (projected) Earnings
—
July 15, 2028
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy Trial Milestone
Phase 2/Phase 3
January 15, 2029
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Trial Milestone
Phase 1/Phase 2
July 15, 2029
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis Trial Milestone
Phase 2/Phase 3
September 15, 2029
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis Trial Milestone
Phase 1/Phase 2
December 15, 2029
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus Trial Milestone
Phase 1/Phase 2
Track CABA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CABA in the tracker
Recent history
Date Event Type Phase
September 14, 2026
8-K filed: Other event Filing
—
August 13, 2026
Quarterly results filed (8-K) Earnings
—
June 3, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
May 14, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
May 14, 2026
Quarterly results filed (8-K) Earnings
—
May 4, 2026
8-K filed: Other event Filing
—
May 4, 2026
Quarterly results filed (8-K) Earnings
—
April 20, 2026
8-K filed: Other event Filing
—
March 23, 2026
Quarterly results filed (8-K) Earnings
—
January 12, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
November 10, 2025
Quarterly results filed (8-K) Earnings
—
October 29, 2025
8-K filed: Other event Filing
—
October 27, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
October 9, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
September 3, 2025
8-K filed: Reg FD disclosure Filing
—
August 7, 2025
Quarterly results filed (8-K) Earnings
—
July 24, 2025
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis Trial Milestone
Phase 1
June 12, 2025
8-K filed: Material agreement, Other event Corporate
—
June 11, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
May 19, 2025
8-K filed: Leadership change Corporate
—
May 15, 2025
Quarterly results filed (8-K) Earnings
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.